LAUSR

About LAUSR
Donate
Contact Us

Follow us:

You are not signed in:

Sign Up!


   Articles with "kras g12c" as a keyword



Impact of a High‐Fat Meal on the Pharmacokinetics of Sotorasib, a KRAS G12C Inhibitor

Sign Up to like & get
recommendations! Published in 2024 at "Clinical Pharmacology in Drug Development"

DOI: 10.1002/cpdd.1452

Abstract: Sotorasib is a small molecule drug that specifically and irreversibly inhibits the KRAS p.G12C mutant protein. This analysis investigated the impact of a high‐calorie high‐fat meal on the pharmacokinetics, safety, and tolerability of sotorasib in… read more here.

Keywords: meal pharmacokinetics; impact high; fat meal; kras g12c ... See more keywords

Differential Response and Resistance to KRAS‐Targeted Therapy

Sign Up to like & get
recommendations! Published in 2025 at "Molecular Carcinogenesis"

DOI: 10.1002/mc.23908

Abstract: KRAS is the most frequently mutated oncogene. In epithelial malignancies such as lung, colorectal, and pancreatic tumors, KRAS is mutated in 25 to above 90% cases. KRAS was considered undruggable for over three decades until… read more here.

Keywords: resistance; kras targeted; resistance kras; response ... See more keywords

Divarasib in the Evolving Landscape of KRAS G12C Inhibitors for NSCLC

Sign Up to like & get
recommendations! Published in 2024 at "Targeted Oncology"

DOI: 10.1007/s11523-024-01055-y

Abstract: Kristen Rat Sarcoma viral oncogene (KRAS) mutations are one of the most common oncogenic drivers found in 12–14% of non-small cell lung cancer (NSCLC) and 4% of colorectal cancer tumors. Although previously difficult to target,… read more here.

Keywords: divarasib evolving; kras g12c; evolving landscape; landscape kras ... See more keywords

Matching-Adjusted Indirect Comparison of Sotorasib Versus Adagrasib in Previously Treated Advanced/Metastatic Non-Small Cell Lung Cancer Harboring KRAS G12C Mutation

Sign Up to like & get
recommendations! Published in 2025 at "Advances in Therapy"

DOI: 10.1007/s12325-025-03259-8

Abstract: Sotorasib and adagrasib are the only treatments approved in the USA and Europe for advanced/metastatic KRAS G12C-mutated non-small cell lung cancer (NSCLC). In the absence of head-to-head trials, a matching-adjusted indirect comparison (MAIC) was conducted… read more here.

Keywords: non small; cancer; cell lung; sotorasib ... See more keywords
Photo from wikipedia

Targeting KRAS(G12C): From Inhibitory Mechanism to Modulation of Antitumor Effects in Patients

Sign Up to like & get
recommendations! Published in 2020 at "Cell"

DOI: 10.1016/j.cell.2020.09.044

Abstract: KRAS mutations are among the most common genetic alterations in lung, colorectal, and pancreatic cancers. Direct inhibition of KRAS oncoproteins has been a long-standing pursuit in precision oncology, one established shortly after the discovery of… read more here.

Keywords: inhibitory mechanism; g12c inhibitory; targeting kras; mechanism modulation ... See more keywords
Photo from wikipedia

KRAS p.G12C mutation occurs in 1% of EGFR-mutated advanced non-small-cell lung cancer patients progressing on a first-line treatment with a tyrosine kinase inhibitor

Sign Up to like & get
recommendations! Published in 2021 at "ESMO Open"

DOI: 10.1016/j.esmoop.2021.100279

Abstract: Background KRAS is mutated in ∼30% of non-small-cell lung cancer (NSCLC) but it has also been identified as one of the mechanisms underlying resistance to tyrosine kinase inhibitors (TKIs) in EGFR-positive NSCLC patients. Novel KRAS… read more here.

Keywords: nsclc; first line; g12c mutation; kras g12c ... See more keywords

Quantifying KRAS G12C Covalent Drug Inhibitor Activity in Mouse Tumors Using Mass Spectrometry.

Sign Up to like & get
recommendations! Published in 2023 at "Analytical chemistry"

DOI: 10.1021/acs.analchem.2c04417

Abstract: The growing opportunities recognized for covalent drug inhibitors, like KRAS G12C inhibitors, are driving the need for mass spectrometry methods that can quickly and robustly measure therapeutic drug activity in vivo for drug discovery research… read more here.

Keywords: mass spectrometry; kras g12c; drug; activity ... See more keywords

Quantitative Assessment of the Target Engagement of a KRAS G12C Inhibitor in Formalin-Fixed Paraffin-Embedded Tumor Tissues Using Immunoaffinity Capture 2D-LC-MS/MS.

Sign Up to like & get
recommendations! Published in 2025 at "Analytical chemistry"

DOI: 10.1021/acs.analchem.5c02696

Abstract: Understanding the target engagement of covalent inhibitors, such as KRAS G12C inhibitors, is essential for evaluating their mechanisms of action and efficacy, particularly given the KRAS G12C mutation's significant role in cancer progression. We previously… read more here.

Keywords: formalin fixed; kras g12c; fixed paraffin; target engagement ... See more keywords

Two new agents target KRAS G12C

Sign Up to like & get
recommendations! Published in 2019 at "Nature Reviews Clinical Oncology"

DOI: 10.1038/s41571-019-0304-3

Abstract: Nature reviews | CliniCal OnCOlOgy Attempts to therapeutically target the products of the RAS oncogenes, frequently mutated in cancer, have had disappointing results thus far. The small molecules MRTX849 and AMG 510, from two independent… read more here.

Keywords: kras g12c; treatment; amg 510; oncology ... See more keywords

Combination therapy of sotorasib and docetaxel overcomes resistance to sotorasib alone in KRAS G12C mutant lung adenocarcinoma.

Sign Up to like & get
recommendations! Published in 2025 at "Journal of chemotherapy"

DOI: 10.1080/1120009x.2025.2503052

Abstract: Mutations in the KRAS gene are the most common gain-of-function mutations found in lung adenocarcinomas. The most prevalent mutation, KRAS G12C, occurs in 13% of lung adenocarcinomas. Sotorasib is an irreversible small molecule inhibitor that… read more here.

Keywords: combination therapy; lung; sotorasib; kras g12c ... See more keywords

Multiple initiatives to conquer KRAS G12C inhibitor resistance from the perspective of clinical therapy

Sign Up to like & get
recommendations! Published in 2023 at "Expert Opinion on Investigational Drugs"

DOI: 10.1080/13543784.2023.2178419

Abstract: ABSTRACT Introduction KRAS G12C targeted covalent inhibitors for cancer therapy are revolutionary. However, resistance to KRAS G12C inhibitors in clinical trials is a proven fact. Areas covered The authors focus on providing coverage and emphasizing… read more here.

Keywords: kras g12c; inhibitor resistance; therapy; resistance ... See more keywords